For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human CCL3/MIP1α Detection Kit is designed for detection and quantitation of human CCL3 (MIP1α) in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
C-C Motif Chemokine 3 (CCL3), also known as Macrophage Inflammatory Protein-1 alpha (MIP-1α), contains 70 amino acids in its mature form. It is a factor produced by macrophages that causes local inflammatory responses in vivo, and induces superoxide production by neutrophils in vitro. CCL3 is involved in the acute inflammatory state and in the recruitment and activation of polymorphonuclear leukocytes. It binds to CCR1, CCR4, and CCR5. CCL3 is known mainly for its activity as a chemotactic cytokine, but may also have a potential role in host defense as a direct antiviral agent. CCL3 has been reported to show a significant direct antiviral activity against HSV-1. It is one of the major HIVsuppressive factors produced by CD8+ T-cells. CCL3 is also an inhibitor of haematopoietic stem cell proliferation.
|Assay Target||CCL3, MIP1α|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.